drugset
drugset / Trial / NCT04240834

Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention

NCT04240834 ↗

Phase 4 Recruiting 1220 enrolled Fu Wai Hospital, Beijing, China
RandomizedParallel-groupSingle-blindTreatment

Summary

The present study is aimed to compare the safety and efficacy of Ticagrelor with low-dose Aspirin versus standard dual anti-platelet therapy (DAPT) in patients with acute coronary syndrome (ACS) at high risk for ischemic events after percutaneous coronary intervention (PCI) and stent implantation.

Timeline

Start
2021-02-01
Primary completion
2025-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 50 mg —
Subject Aspirin Small molecule 75 mg —
Background Ticagrelor Small molecule 90 mg —

Indications

acute coronary syndrome